{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-031695","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2022-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.133525+00:00","generated_at":"2026-06-21T05:54:42.148952+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sangamo Therapeutics presents updated proof-of-concept data for BIVV003 and giroctocogene fitelparvovec at ASH","bullets":["BIVV003 in sickle cell disease: 3 of 4 Group 1 patients maintained HbF >30% with no severe VOCs up to 30 months.","Group 2 Patient 5 achieved HbF 45% and total Hb 12.4 g/dL at week 26 using improved manufacturing.","Hemophilia A gene therapy: highest dose cohort had zero annualized bleeding rate in first year post-infusion.","Mean FVIII activity at week 156 was 25.5% of normal in highest dose cohort with no inhibitor development.","No treatment-related serious adverse events for BIVV003; one grade 3 hypotension event in hemophilia A study resolved."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-031695","json":"https://secwatch.observer/filing/0001628280-22-031695.json","markdown":"https://secwatch.observer/filing/0001628280-22-031695.md","text":"https://secwatch.observer/filing/0001628280-22-031695.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828022031695/0001628280-22-031695-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828022031695/sgmo-20221210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:54:42.148952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}